| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 4921.0 | 4197.0 | 3178.0 |
| Other income | -12.0 | -17.0 | -37.0 |
| Total income | 4909.0 | 4180.0 | 3141.0 |
| Profit before exceptional items & tax | 754.0 | 595.0 | 738.0 |
| Exceptional items | 21.0 | 66.0 | 0.0 |
| Profit before tax | 733.0 | 529.0 | 738.0 |
| Net profit | 566.0 | 364.0 | 548.0 |
| Operating margin | 14.9% | 12.7% | 23.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +3.30% |
|---|---|
| Net profit, quarter on quarter | +55.50% |
| Revenue, year on year | +54.80% |
| Operating profit, year on year | -1.20% |
| Operating profit, quarter on quarter | +51.70% |
NSE results filing, NSE: TORNTPHARM. Figures extracted from the filing.
Torrent Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,988.50
- Market cap
- ₹1,89,747 Cr
- Revenue (annual)
- ₹13,980 Cr
- Net profit (annual)
- ₹2,163 Cr
- P/E (TTM)
- 87.0×Sector 50.4×
- Promoter holding
- 60.78%-7.53% QoQ
- FII holding
- 17.97%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Torrent Pharmaceuticals Ltd
All →Torrent Pharmaceuticals Annual General Meeting
Shareholders approved the appointment of Ms. Shanti Ekambaram as an Independent Director of Torrent Pharmaceuticals via Postal Ballot.
Torrent Pharmaceuticals Earnings Call Transcript: Key Takeaways
Torrent Pharma delivered strong Q1 performance with revenues up 55% following the JB Chemicals merger completion. EBITDA margins jumped to 33.8% driven by accelerated cost synergies.
- Call
- Guides 10% growth
Torrent Pharmaceuticals Earnings Call: Key Takeaways
Torrent Pharma Q4 FY26 revenue rose 42% to ₹4,197cr, driven by JB Pharma consolidation. Combined EBITDA margin stood at 32.3%, with focus on Semaglutide ramp-up in India and synergy execution.
Torrent Pharmaceuticals Earnings Call: Key Takeaways
Torrent Pharma delivered strong Q4 growth led by India and Brazil, while successfully integrating Curatio and JB Pharma assets.
Torrent Pharmaceuticals Q4 FY26 Results: Net Profit ₹364 Cr, Down 26.9% YoY
Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,197 Cr (+41.8% YoY) and net profit of ₹364 Cr (-26.9% YoY) for Q4 FY26.
- Key figure
- Net profit ₹364 Cr · -26.9% YoY